From the Editor: PARP Inhibitors, Biomarker Research, and Gene Editing

Alex A. Adjei, MD, PhD

Dear Colleagues,

Welcome to the first issue ofThe Journal of Targeted Therapies in Cancerfor 2015.

The Journal highlights advances in targeted therapies in cancer for oncology professionals in the community who wish to translate this research into practice.The Journalalso includes other cancer therapies and research in precision medicine, a topic that has garnered increased media attention since President Barack Obama announced the Precision Medicine Initiative that promises to further move this research forward.

The Journal of Targeted Therapies in Cancerhas been on top of these clinical advances for the past 3 years, bringing readers the latest in original, peer-reviewed research articles. This issue features an article on antibody drug conjugates, and how these agents may yet fill a void in targeted treatment for breast cancer. You will also find details on PARP-1 inhibitors and their emerging role in the treatment of lung cancer. A third research article involves novel targets in relapsed and relapsed/refractory multiple myeloma.

You will also see news on: biomarker research in gastrointestinal stromal tumors, a collaboration in gene editing, recent trial data in the treatment of pancreatic NETS, and updated information on mutations in breast cancer.

This issue’s Clinical Advances section contains information on the potential of anti-androgen therapy in patients with breast cancer. Another breast cancer feature includes a trial studying a nab-paclitaxel-based chemotherapy combination as first-line treatment for triple-negative metastatic breast cancer. This month also features key opinion leaders in 3 disease states discussing plasma-based molecular profiling.

We hope you enjoy this first issue of 2015, and as always, please send us your suggestions on topics you would like to see us highlight so that we continue to improve JTT to serve your needs.

— Alex A. Adjei, MD, PhD